Skip to main content
SIU 2026 Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench to Bedside
Bench to Bedside
SIU@U
SIU@U

    Karima Oualla

    Associate Professor of Medical Oncology
    Hassan II University Hospital, Morocco

    Karima Oualla, MD, MSc

    Associate Professor of Medical Oncology, Faculty of Medicine and Pharmacy, University Sidi Mohamed Ben Abdellah, Fez, Morocco
    Referent on GU cancers Hassan II University Hospital-Morocco
    Council member of the Global Society of Rare Genitourinary Tumors (GSRGT)
    Joint committee International Bladder Cancer Group IBCG-GSRGT
    World Bladder Cancer Patients Coallition Scientific Advisory Board
    Short biography:
    Dr Oualla completed her medical training at University Sidi Mohamed Ben Abdellah prior to practicing as a Medical Oncologist at Hassan II University Hospital. She joined Institut Jules Bordet in Brussels, Belgium, as an assistant doctor (2012–2013). Dr Oualla holds a certificate of specialization in Medical Oncology from the Université Libre de Bruxelles, and completed a 3-year postgraduate course in Medical Oncology (European Organisation for Research and Treatment of Cancer [EORTC]-affiliated National Belgian Programme for Inter-University Faculty).
    Dr Oualla was awarded a fellowship by the European Society of Medical Oncology (ESMO) on Onco-Urology at the Istituto Nazionale dei Tumori, in Milan, Italy where she worked in Onco-Urology Unit. In 2015, she joined the Cancer Prevention and Control Research Training Programme at the Department of Public Health in the University of South Florida, in Tampa, FL, USA, funded by the National Institutes of Health (NIH) Fogarty International Center, Bethesda, MD, USA, and Moffitt Cancer Center, Tampa (2015–2016). She completed a master’s degree in Science at Ulm University,Germany in 2020.
    Dr Oualla was designated as an ambassador of the European School of Oncology for the years 2023 and 2024.
    Dr Oualla serves on the leadership Council of the Global Society of Rare Genitourinary Tumors (GSRGT), and the scientific committee of the International Bladder Cancer Group (IBCG) and the Specialty editor on GU at ESMO Open.

    Disclosure information not submitted.

    Presentation(s):